Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic …
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Alnylam Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
All monetary values are presented in USD ($). E stands for Estimate.
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -1.4500 | -2.715 | 47 | 81 | -89 | -439 | -92 | -478 | -92 | -498 | 27 | 52 |
| 2015 | -4.8500 | -3.336 | 50 | 43 | -360 | -271 | 36 | -253 | -184 | -276 | 44 | 45 |
| 2016 | -3.4500 | -4.879 | 41 | 42 | -290 | -402 | -296 | -387 | -296 | -416 | 60 | 44 |
| 2017 | -4.7900 | -5.286 | 47 | 70 | -410 | -463 | -424 | -450 | -424 | -471 | 89 | 74 |
| 2018 | -5.4200 | -7.650 | 89 | 70 | -490 | -735 | -500 | -729 | -500 | -789 | 199 | 74 |
| 2019 | -7.5700 | -7.899 | 74 | 222 | -761 | -878 | -835 | -822 | -814 | -929 | 382 | 234 |
| 2020 | -8.1100 | -7.203 | 219 | 475 | -886 | -777 | -939 | -659 | -939 | -772 | 479 | 502 |
| 2021 | -7.4600 | -6.444 | 492 | 820 | -858 | -723 | -771 | -724 | -828 | -608 | 588 | 527 |
| 2022 | -7.2000 | -8.953 | 844 | 1,013 | -852 | -770 | -709 | -775 | -708 | -565 | 620 | 513 |
| 2023 | -9.3000 | -3.478 | 1,037 | 1,826 | -1,131 | -440 | -894 | -852 | -785 | -621 | 770 | 564 |
| 2024 | -3.5200 | -1.976 | 1,828 | 2,231 | -440 | -246 | -228 | -1,708 | -282 | -1,765 | 795 | 2,359 |
| 2025 | - | -1.083 | - | 2,628 | - | -193 | - | -2,011 | - | -2,079 | - | 2,779 |
| 2026 | - | 2.F12X/td> | - | 2.F12X/td> | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 1.F13X/td> | - | 1.F13X/td> | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 0.F14X/td> | - | 0.F14X/td> | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |